在接受激素治疗的晚期前列腺癌患者中增强了血管炎症
Holger Einspieler1, Dina Muin1, Ilva Kristiana Langrate1
1Department of Biomedical Imaging and Image-Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Währinger Gürtel 18-20, Vienna, 1090, Austria.
概括
前列腺癌的激素治疗 (PCa) 增加了动脉炎症,正如[18F]FDG-PET成像显示的那样. 这一发现可能解释了接受激素治疗的PCa患者心血管风险更高.
科学领域:
- 心血管成像 - 心血管成像
- 在瘤学瘤学.
- 核医学就是核医学.
背景情况:
- 前列腺癌 (PCa) 的激素治疗减缓了疾病的进展,但增加了心血管疾病 (CVD) 的风险.
- 动脉炎症是动脉样硬化的一个标志物,可以使用[18F]FDG-PET成像来评估.
- [18F]FDG-PET也在PCa中用于评估瘤的攻击性.
研究的目的:
- 为了研究激素治疗对PCa患者动脉炎症的影响,使用[18F]FDG-PET.
- 探索PCa激素治疗与心血管风险增加之间的潜在联系.
主要方法:
- [18F]FDG-PET/CT扫描对32名接受激素治疗的PCa患者和17名不接受激素治疗的年龄匹配对照进行了扫描.
- 在主要动脉段中分析了感兴趣的区域,上腔静脉 (SVC) 用于背景校正.
- 计算了目标与背景比率 (TBR) 和化斑块 (CP) 评分.
主要成果:
- 与对照组相比,接受激素治疗的患者在多个大动脉段和联合动脉分析中显示出明显更高的TBRmax值 (p < 0.05).
- 腹部和上升大动脉的TBR平均值也显著升高,以及激素治疗组的联合动脉分析 (p < 0.05).
- 两组之间在年龄,BMI,脂质样本,CRP或CP得分方面没有发现显著差异.
结论:
- 接受激素治疗的PCa患者表现出[18F]FDG-PET检测到的动脉炎症增加.
- 这些发现表明,PCa激素治疗与该人群中观察到的心血管风险升高之间存在潜在的联系机制.
相关概念视频
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
260
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
260
01:20Disorders of the Male Reproductive System
617
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
617
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
256
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
256
01:24Regulation of Angiogenesis and Blood Supply
2.7K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.7K
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
228
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
228